2017年甘肃省肿瘤登记地区肝癌发病和死亡分析

摘要/Abstract

摘要： 目的: 分析2017年甘肃省肝癌发病和死亡情况,为制定肝癌防治策略提供依据。
方法: 收集整理2020年甘肃省23个肿瘤登记点上报的恶性肿瘤发病、死亡及人口资料登记数据,10个登记点数据符合质量控制标准。按性别、城乡和年龄组分层计算肝癌发病率和死亡率,采用2000年中国标准人口构成和Segi世界标准人口年龄构成分别计算中国人口标化率（简称中标率）、世界人口标化率（简称世标率）。
结果: 2017年甘肃省肿瘤登记地区新发肝癌病例774例,占全部恶性肿瘤发病构成的7.90%,位居恶性肿瘤发病顺位第5位,发病率为23.35/10万（男性31.89/10万,女性14.43/10万）,中标率为16.19/10万,世标率为15.95/10万,0~74岁累积发病率为1.87%;城市地区发病率为23.25/10万,中标率为15.20/10万;农村地区发病率为23.55/10万,中标率为18.91/10万。2017年甘肃省肿瘤登记地区肝癌死亡病例为623例,占全部恶性肿瘤死亡构成的12.16%,位居恶性肿瘤死亡顺位第3位,死亡率为18.80/10万（男性25.04/10万,女性12.27/10万）,中标率为13.03/10万,世标率为12.88/10万,累积发病率（0~74岁）为1.49%;城市地区死亡粗率为18.94/10万,中标率为12.29/10万;农村地区死亡粗率为18.51/10万,中标率为15.35/10万。2017年甘肃省肿瘤登记地区肝癌发病率和死亡率最高的地区均为景泰县。
结论: 甘肃省肝癌发病率和死亡率仍较高,且存在地区和性别差异,应根据实际情况和肝癌流行特点,积极开展健康宣教,落实肝癌危险因素综合防控,推进肝癌早诊、早治工作,以筛查为抓手,多维度合力推进甘肃省肝癌防控工作。

关键词: 肝癌, 发病率, 死亡率, 肿瘤登记, 甘肃省

Abstract: Objective:To analyze the incidence and mortality of liver cancer in Gansu Province in 2017, and provide a basis for formulating prevention and treatment strategies for liver cancer.
Method:We collected registration data of cancer incidence, mortality and population data reported by 23 cancer registration points in Gansu Province in 2020, and the data from 10 registration points meet the quality control standards. We calculated the incidence and mortality of liver cancer according to gender, areas (urban and rural) and age groups, and use the standard population composition of China in 2000 and Segi's world standard population age composition to calculate the standardized rate of Chinese population (ASR China) and the standardized rate of world population (ASR World).
Result:In 2017, there were 774 new cases of liver cancer in the cancer registration area of Gansu Province, accounting for 7.90% of all malignant cancers, ranking fifth in the incidence of malignant cancers, with an incidence rate of 23.35/100 000 (male 31.89/100 000, female 14.43/100 000), ASR China was 16.19/100 000, ASR World was 15.95/100 000, and the cumulative rate was 1.87%; the incidence rate in urban areas was 23.25/100 000, and ASR China was 15.20/100 000; in rural areas, the crude incidence rate in the region was 23.55/100 000, and ASR China was 18.91/100 000. In 2017, there were 623 new cases dying from liver cancer in the cancer registration area of Gansu Province, accounting for 12.16% of all cancer deaths ranking third among cancer death profiles, with a mortality rate of 18.80/100 000 (male 25.04/100 000, female 12.27/100 000), ASR China was 13.03/100 000, ASR World was 12.88/100 000, and the cumulative rate was 1.49%; the crude mortality rate in urban areas was 18.94/100 000, and ASR China was 12.29/100 000; The crude mortality rate in rural areas was 18.51/100 000, and ASR China was 15.35/100 000. In 2017, the area with the highest incidence and mortality of liver cancer in the cancer registration area of Gansu Province was Jingtai County.
Conclusion:The incidence and mortality of liver cancer in Gansu Province are still high, and there are regional and gender differences. According to the actual situation and the epidemiological characteristics of liver cancer, health education should be actively carried out, comprehensive prevention and control of liver cancer risk factors should be implemented, and early diagnosis and treatment of liver cancer should be promoted. Taking screening as the starting point, multi-dimensional joint efforts to promote the prevention and control of liver cancer in Gansu Province.

Key words: Hepatic carcinoma, Incidence, Mortality, Cancer registration, Gansu Province

袁浩冉, 丁高恒, 陈莉莉, 刘玉琴. 2017年甘肃省肿瘤登记地区肝癌发病和死亡分析[J]. 肝癌电子杂志, 2022, 9(1): 55-60.

Yuan Haoran, Ding Gaoheng, Chen Lili, Liu Yuqin. Analysis of the incidence and mortality of liver cancer in Gansu cancer registration areas, 2017[J]. Electronic Journal of Liver Tumor, 2022, 9(1): 55-60.

参考文献

[1] SUNG H, FERLAY J, SIEGEL R L, et al.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[2] 郑荣寿, 孙可欣, 张思维, 等. 2015年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2019, 41(1): 19-28.
[3] 安澜, 曾红梅, 郑荣寿, 等. 2015年中国肝癌流行情况分析[J]. 中华肿瘤杂志, 2019, 41(10): 721-727.
[4] 张洁, 黄瑜, 丁高恒, 等. 2009—2015年甘肃省肿瘤登记地区肝癌流行特征及变化趋势分析[J]. 中国癌症防治杂志, 2021, 13(2): 132-137.
[5] 国家癌症中心. 中国肿瘤登记工作指导手册(2016)[M]. 北京: 人民卫生出版社, 2016: 59-75.
[6] GURADO M P, EDWARDS B, SHIN H R, et al.Cancer incidence in five continents. Volume Ⅸ[M]. Lyon: IACR, 2008: 1-837.
[7] BRAY F, PARKIN D M.Evaluation of data quality in the cancer registry: principle and methods. Part Ⅰ: comparability,validity and timeliness[J]. Eur J Cancer, 2009, 45(5): 747-755.
[8] PARKIN D M, BARY F.Evaluation of data quality in the cancer registry: principle and methods. Part Ⅱ: comparability, validity and timeliness[J]. Eur J Cancer, 2009, 45(5): 756-764.
[9] FELAY J. The IARC crgTools program[EB/OL]. http://www.iacr.com.fr/index.php?option=com_content&view=category&layout=blog&id=68&Itemid=445, 2017-10-01.
[10] 刘玉琴, 李文英, 朱奕潼, 等. 2013年甘肃省肿瘤登记地区恶性肿瘤发病与死亡分析[J]. 中国肿瘤, 2018, 27(4): 246-255.
[11] 李秋林, 曹骥, 容敏华, 等. 2016年广西肿瘤登记地区恶性肿瘤发病和死亡分析[J]. 中国癌症防治杂志, 2020, 12(1): 44-51.
[12] 周薇薇, 郑荣寿, 邓颖, 等. 2013年四川省肿瘤登记地区恶性肿瘤发病和死亡分析[J]. 中国肿瘤, 2018, 27(7): 489-496.
[13] 鲍萍萍, 吴春晓, 张敏璐, 等. 2015年上海市恶性肿瘤流行特征分析[J]. 中国癌症杂志, 2019, 29(2): 81-99.
[14] 郭雪蓉, 马朝辉, 曹凌, 等. 2016年山西省肿瘤登记地区肝癌发病与死亡分析[J]. 中国癌症防治杂志, 2021, 13(2): 155-158.
[15] SCHÜTTE K, BORNSCHEIN J, MALFERTHEINER P. Hepatocellular carcinoma--epidemiological trends and risk factors[J]. Dig Dis, 2009, 27(2): 80-92.
[16] 罗好曾, 米登海, 李玉国, 等. 甘肃省武威市肝癌危险因素流行病学研究[J]. 肿瘤研究与临床, 2010, 22(2): 134-137.
[17] 俞顺章, 穆丽娜, 蔡琳, 等. 饮水等三大环境危险因素与肝癌——泰兴市肝癌病例对照研究[J]. 复旦学报(医学版), 2008, 35(1): 31-38.
[18] 张学飞, 李述刚, 闫贻忠, 等. 2006—2010年中国肿瘤登记地区恶性肿瘤疾病负担研究[J]. 中华肿瘤防治杂志, 2015, 22(10): 733-737.
[19] MASSARWEH N N, El-SERAG H B. Epidemiology of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma[J]. Cancer Control, 2017, 24(3): 1073274817729245.
[20] LIU Y Y, LIU Y K, HU W T, et al.Elevated heme impairs macrophage phagocytosis in endometriosis[J]. Reproduction, 2019, 158(3): 257-266.
[21] 陈建国, 朱健, 张永辉, 等. 肝癌流行趋势的改变: 基于启东40年癌症登记资料的分析[J]. 中国肿瘤, 2014, 23(8): 621-628.
[22] 王宇婷, 陈陶阳, 朱健, 等. 肝癌高发区人群新生儿乙型肝炎疫苗接种对肝癌的预防效果[J]. 中华预防医学杂志, 2018, 52(4): 402-408.
[23] 李慧, 高丽, 张晓曙, 等. 甘肃省乙肝疫苗接种与乙肝病毒感染相关性分析[J]. 中国公共卫生, 2011, 27(11): 1380-1382.
[24] 缪苗苗, 万志娜, 丁丽, 等. 甘肃省居民乙肝防治知识态度行为调查分析[J].当代医学, 2020, 26(1): 15-17.
[25] HEIMBACH J K, KULIK L M, FINN R S, et al.AASLD guidelines for the treatment of hepatocellular carcinoma[J]. Hepatology, 2018, 67(1): 358-380.
[26] 李元林, 王莹, 施岱瑜, 等. 甘肃省慢性病患者健康素养水平及其影响因素分析[J]. 中国农村卫生事业管理, 2021, 41(3): 222-228.